Participant flow

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma · Source last updated 2019-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All subjects were males with advanced prostate carcinoma. They were injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects were followed until day 336. Leuprolide Mesylate: Subcutaneous injection of 50mg Leuprolide Mesylate

   id

   FG000

   title

   Leuprolide Mesylate 50mg

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         137

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         137

      type

      ITT

   3. achievements

      1. group Id

         FG000

         num Subjects

         124

      type

      PP

   4. achievements

      1. group Id

         FG000

         num Subjects

         31

      type

      PK Subgroup

   5. achievements

      1. group Id

         FG000

         num Subjects

         122

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         15

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice